Skip to content
The Policy VaultThe Policy Vault

Sprycel (dasatinib) — United Healthcare

Myeloid, lymphoid, or mixed lineage neoplasms with eosinophilia and ABL1 rearrangement

Initial criteria

  • Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia
  • AND Patient has an ABL1 rearrangement

Reauthorization criteria

  • Patient does not show evidence of progressive disease while on Sprycel therapy

Approval duration

12 months